Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

TP53 mutations and breast cancer prognosis : particularly poor survival rates for cases with mutations in the zinc-binding domains

Børresen, A L ; Andersen, T I ; Eyfjörd, Jórunn Erla ; Cornelis, R S ; Thorlacius, Steinunn ; Borg, A LU ; Johansson, U LU ; Theillet, C ; Scherneck, S and Hartman, S , et al. (1995) In Genes, Chromosomes and Cancer 14(1). p.5-71
Abstract

Acquired mutations in TP53 as well as immunohistochemically detectable protein expression have been implicated as prognostic factors for breast cancer. We have evaluated the relationship between mutations detected in 119 breast tumours and various clinicohistopathological indices, stratifying the mutations according to the functional domains as defined by the recent elucidation of the crystal structure of the protein. Patients with missense mutations located in regions encoding parts of the protein involved in zinc-binding had significantly decreased disease-free and overall survival relative to patients whose tumours had mutations in other domains. These results indicate that these biochemically defined domains also have biological... (More)

Acquired mutations in TP53 as well as immunohistochemically detectable protein expression have been implicated as prognostic factors for breast cancer. We have evaluated the relationship between mutations detected in 119 breast tumours and various clinicohistopathological indices, stratifying the mutations according to the functional domains as defined by the recent elucidation of the crystal structure of the protein. Patients with missense mutations located in regions encoding parts of the protein involved in zinc-binding had significantly decreased disease-free and overall survival relative to patients whose tumours had mutations in other domains. These results indicate that these biochemically defined domains also have biological relevance in terms of breast cancer disease course, and suggest that some mutations in TP53, more than others, can contribute to the development of clinically more aggressive and perhaps treatment resistant breast tumours. When confirmed, this will be of potential importance in predicting the clinical behaviour of breast cancer and its responsiveness to therapy.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Age of Onset, Aged, Aged, 80 and over, Binding Sites, Breast Neoplasms/genetics, Cohort Studies, DNA Mutational Analysis, Female, Genes, p53, Humans, Middle Aged, Mutation, Prognosis, Zinc
in
Genes, Chromosomes and Cancer
volume
14
issue
1
pages
5 - 71
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:8527388
  • scopus:0029084995
ISSN
1045-2257
DOI
10.1002/gcc.2870140113
language
English
LU publication?
no
id
d92977a6-e1da-4b01-8eb1-99ccf7b76483
date added to LUP
2019-05-27 22:49:42
date last changed
2024-05-15 10:29:55
@article{d92977a6-e1da-4b01-8eb1-99ccf7b76483,
  abstract     = {{<p>Acquired mutations in TP53 as well as immunohistochemically detectable protein expression have been implicated as prognostic factors for breast cancer. We have evaluated the relationship between mutations detected in 119 breast tumours and various clinicohistopathological indices, stratifying the mutations according to the functional domains as defined by the recent elucidation of the crystal structure of the protein. Patients with missense mutations located in regions encoding parts of the protein involved in zinc-binding had significantly decreased disease-free and overall survival relative to patients whose tumours had mutations in other domains. These results indicate that these biochemically defined domains also have biological relevance in terms of breast cancer disease course, and suggest that some mutations in TP53, more than others, can contribute to the development of clinically more aggressive and perhaps treatment resistant breast tumours. When confirmed, this will be of potential importance in predicting the clinical behaviour of breast cancer and its responsiveness to therapy.</p>}},
  author       = {{Børresen, A L and Andersen, T I and Eyfjörd, Jórunn Erla and Cornelis, R S and Thorlacius, Steinunn and Borg, A and Johansson, U and Theillet, C and Scherneck, S and Hartman, S and Cornelisse, C and Hovig, E. and Devilee, P}},
  issn         = {{1045-2257}},
  keywords     = {{Adult; Age of Onset; Aged; Aged, 80 and over; Binding Sites; Breast Neoplasms/genetics; Cohort Studies; DNA Mutational Analysis; Female; Genes, p53; Humans; Middle Aged; Mutation; Prognosis; Zinc}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{5--71}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Genes, Chromosomes and Cancer}},
  title        = {{TP53 mutations and breast cancer prognosis : particularly poor survival rates for cases with mutations in the zinc-binding domains}},
  url          = {{http://dx.doi.org/10.1002/gcc.2870140113}},
  doi          = {{10.1002/gcc.2870140113}},
  volume       = {{14}},
  year         = {{1995}},
}